– The vaccine maker saw its shares fall 4.3% after the company said it expects to report data from its Covid-19 vaccine trials involving 2- to 5-year-olds by March. The company could file for approval to vaccinate that age group if the data is supportive, it said in a statement.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Corporate profits are breaking records, what with their “inflation”